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Patients with advanced Parkinson’s disease (PD) experience body weight loss and reductions in the most common cardiovascular
risk factors. At present, the pathogenetic mechanisms involved have not been elucidated. Increased serum concentrations of
adiponectin, which possesses antiatherogenic and anti-inﬂammatory properties, are associated with a reduction in cardiovascular
risk. The objective of this study wasto determine adiponectin serum concentrationsin PD patients. Thirty PDpatients underwent
a full nutritional status assessment, including the determination of adiponectin serum concentrations. Mean ± SD adiponectin
concentrations were 9.59 ± 5.9μg/mL (interquartile range: 5.92–12.9μg/mL). In PD patients, adiponectin serum levels were
similartothoseinnormal-weight,healthy,youngsubjects andsigniﬁcantlyhigherthanthatinanaged-matched groupofmorbidly
obese subjects. Further studies are warranted to establish the role of adiponectin in the management of PD patients.
1.Introduction
PatientswithParkinson’s disease (PD)experience weight loss
in the advanced stages of the disease, resulting in a reduction
in body mass index (BMI) [1–3] .W e i g h tl o s sa p p e a r st o
involve mainly adipose tissue and to spare (or even increase)
fat-free mass [4, 5] although not all ﬁndings reported in the
literature are consistent with this conclusion [6].
Reductions in the most common cardiovascular risk
factors (elevated concentrations of fasting glucose, LDL
cholesterol, triglycerides, and arterial hypertension) have
been recorded in PD patients [7, 8]a sw e l la sa ni m p r o v e -
ment in HDL cholesterol [9]. The pathogenetic mechanisms
involved have not been elucidated. According to some
authors,thephenomenonmaybeinducedbythemodulating
activity of levodopa therapy on the sympathetic system [10].
Ithasbeenshownthatthereisarelationshipbetweenadi-
pose tissue and cardiovascular risk mediated by adipokines,
such as adiponectin. Adiponectin is a protein synthesized by
whitefattissue,whose concentrationsinhumanserumrange
from 3 to 30μg/mL [11–14]. High serum adiponectin con-
centrations, which are inﬂuenced by a reduction in fat mass
[11],areassociated withareductionintherisk ofmyocardial
infarction, even after adjustment for HDL, LDL, and BMI
levels [15], whereas low-adiponectin concentrations are
associated with the risk of developing type II diabetes [16]
and hypertension [17]. It is well known that adiponectin
exerts important vascular and cardiac eﬀects, especially in
preserving endothelial function, protecting it from ischemic
and reperfusion damage, and in stimulating angiogenesis;
it also possesses anti-inﬂammatory, antiapoptotic and anti-
hypertrophic properties [18]. Furthermore, it modulates
inﬂammation, reducing the synthesis of proinﬂammatory
cytokines, such as TNFα [19]. Overall, it, therefore, appears
that adiponectin has antiatherogenic eﬀects that could
explain how it is able to reduce cardiovascular risk.
Todate,thedatareportedintheliteratureonadiponectin
concentrations are related to the general population or to
subjects with diﬀerent degrees of obesity, diabetes, and/or
dyslipidemia.To ourknowledge,nodatainPDpatientsexist.2 Parkinson’s Disease
The objective of our study was to determine serum
adiponectin concentrationsi nag r o u po fP Dp a t i e n t si n
advanced stages of the disease [20, 21], to assess whether
there is a correlation between adiponectin concentrations,
body composition, and metabolic markers in this patient
population.
2.Materialsand Methods
2.1. Study Population. We recruited 30 patients suﬀering
from PD admitted to the Parkinson Institute (Istituti Clinici
di Perfezionamento (ICP) Hospital, Milan, Italy) consecu-
tively.PDwas diagnosed accordingtoUKBrainBankcriteria
[22]. All enrolled patients were on treatment with levodopa
and a dopamine agonist for neurological symptoms. No
patients were on treatment prescribed to decrease total
cholesterol levels. Patients had a mean duration of PD of 8.7
± 6.1 years (range 5–20 years).
Twenty-eight morbidly obese subjects (14 males, 14
females; mean ± SD age 68.4 ± 11 years, mean ± SD body
mass index (BMI, kg/m2) 43.5 ± 5.3) were enrolled in the
study. Due to the higher degree of obesity, some of the obese
patients were in treatment with lipid-lowering drugs. Blood
samples were obtained in the morning, after an overnight
fast.
Thirty-three (22 males and 11 females) normal-weight
(BMI 22.9 ± 2), metabolically healthy volunteers, aged 36 ±
6 years, were also enrolled. In this latter group, arterial
pressure was assessed, and it was in the normality range
for all subjects. They were not on treatment prescribed to
decrease total cholesterol levels. They had normal glucose,
total cholesterol, and insuline levels. Blood samples were
obtained in the morning, after an overnight fast.
2.2.Assessments. Allpatientsunderwent assessment ofnutri-
tional status.
Thenutritionalassessmentsincludedthefollowingsteps:
(i) complete nutritional examination (family history,
lifestyle, medical history including pharmacological
treatment, dietary history, body weight history, and
assessment of any complication of nutritional inter-
est);
(ii) body composition evaluation by anthropometric
methods (described in the following section);
(iii) assessment of nutritional status by measuring bio-
chemical parameters and adiponectin serum level
quantiﬁcation.
During the hospital stay, the patients underwent also a
neurologicalexaminationdesignedtoﬁne-tunethediagnosis
and adjust treatment accordingly.
The anthropometric assessment included measurement
of body weight, height and calculation of body mass index
(BMI) and of the main body circumferences (waist at the
anterior superior iliac crest and arm).
Venous blood sampling was carried out in the morning,
after an overnight fast, for the following laboratory tests:
(i) routine tests: total cholesterol, HDL cholesterol, cre-
atinine, transaminases, blood glucose, triglycerides,
and uric acid;
(ii) indicators of nutritional status: plasma transferrin,
albumin, and total lymphocytes.
The analyses were carried out at the Laboratory of ICP
Hospital, according to standard methods.
Total adiponectin levels in serum were determined by
an enzyme-linked immunoabsorbent assay (ELISA Total
Human Adiponectin Kit, TECOmedical GROUP, Sissach,
Switzerland). Total adiponectin detection limit was 1.56–
100ng/mL.
2.3. Statistical Analysis. Patients involved in the study were
numbered progressively, and the relative anonymous data
were used for the creation of a database protected by pass-
word. The following variables were collected: body weight
(kg), height (meters), BMI (Kg/m2), waist circumference
(cm), arm circumference (cm), blood glucose (mg/dL), total
cholesterol (mg/dL), HDL cholesterol (mg/dL), triglycerides
(mg/dL), creatinine (mg/dL), albumin (g/dL), transferrin
(mg/dL), AST (U/L), ALT (U/L), duration of disease (years),
daily intake of levodopa (mg), and adiponectin (μg/mL).
A Shapiro-Wilk W-test was performed systematically
to test the normality of data distribution. In case of lack
of normality, data were log-transformed. The statistical
analysis of data was carried out using JMP software, version
3.2.6, SAS Institute Inc, USA. A P-value <.05 was the
set limit for statistical signiﬁcance. Means were compared
using ANOVA/Student’s t-test, and Pearson’s test was used
to assess correlations between two variables at a time.
The patient population was subdivided into two groups
according to whether their HDL cholesterol was above or
below the threshold for protection against cardiovascular
disease: ≥50mg/dL (PD HDL-high group) and <50mg/dL
(PDHDL-lowgroup).To analyze this comparison, Wilcoxon
test(for nonparametric data)and/orANOVAtestwere used.
3.Results
The biochemical and clinical features of the studied PD
patients are summarized in Table 1. Most of the patients
were males (64%). No diﬀerences between genders were
recorded, except for an anthropometric parameter, such as
waist circumference (P = .02) and fat mass/fat-free mass
percentage (P<. 05), as expected. Adiponectin serum
concentrations in PD patients were on average 9.59 ±
5.9μg/mL (mean ± SD) with an interquartile range of 5.92–
12.9μg/mL.
In PD patients, the adiponectin serum levelswere similar
to adiponectin serum levels in normal-weight, healthy
subjects (9.02 ± 6.7μg/mL) but signiﬁcantly higher than
those recorded in an aged-matched group of morbidly
obese subjects (6 ± 2.9 μg/mL), as shown in Figure 1(a).
In PD patients, a signiﬁcant positive correlation was found
between serum adiponectin and HDL cholesterol concen-
trations (Figure 1(b))( R h o = 0.53, P = .003) which
remained signiﬁcant even after adjustment for gender, age,Parkinson’s Disease 3
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Figure 1: (a) adiponectin serum levels (μg/mL) in normal-weight PD and OB subjects. Mean ± SD, are shown. ∗∗P-value <.01. (b)
correlation between adiponectin serum levels (μg/mL) and HDL cholesterol levels (mg/dL) in PD patients (n = 30) (Rho = 0.53, P = .003).
Table 1: Biochemical, anthropometric, and clinical characteristics
of the Parkinson disease (PD) patient population enrolled, n = 30,
M/F = 19(64%)/11(36%).Data are expressed as mean ± SD.
Parameter Data (mean ± standard deviation)
Age (years) 62.4 ± 10.63
Duration of disease (years) 8.7 ± 6.1
Levodopa (mg) 532.7 ± 220.1
BMI (Kg/m2) 25.5 ± 4.2
Weight (Kg) 71.8 ± 15.7
Waist circumference (cm) 95.23 ± 15.8
Arm circumference (cm) 28.4 ± 3.97
Fat mass (%) 32.3 ± 7.74
Fat-free mass (%) 67.7 ± 6.7
Albumin (g/dL) 3.89 ± 0.2
Transferrin (mg/dL) 243.6 ± 40.5
Creatinine (mg/dL) 0.67 ± 0.1
ALT (U/L) 13.5 ± 6.6
AST (U/L) 16.8 ± 4.9
Triglycerides (mg/dL) 97.5 ± 46.3
Glucose (mg/dL) 87.5 ± 14.9
Total cholesterol (mg/dL) 189.0 ± 46.21
HDL cholesterol (mg/dL) 51.8 ± 16.4
Adiponectin (μg/mL) 9.59 ± 5.97
and duration of disease. In the PD patient group, there was
an inverse correlation between adiponectin serum levels and
waist circumference (Rho =− 0.37, P = .05), body weight
(Rho =− 0.47, P = .009), fasting glucose concentrations
(Rho =− 0.47, P = .01), and triglyceride concentrations
(Rho =− 0.48, P = .01). No correlation was observed
between adiponectin serum levels and BMI, nor between
adiponectin and fat mass fat-free mass percentage.
The association between high levels of HDL cholesterol
and a decreased risk for cardiovascular disease has been well
established through epidemiological and clinical studies. We
then decided to analyze our patients regrouped for HDL
cholesterol levels: patients with HDL ≥ 50mg/dL were in the
PD HDL-high group while patients with HDL < 50mg/dL
were in the PD HDL-low group. Sixteen PD patients
belongedtothePDHDL-highgroup(HDL ≥ 50mg/dL)and
14 to the PD HDL-low group (HDL < 50mg/dL). These two
subgroups did not diﬀer in terms of age, duration of disease,
levodopadosage,andtotalcholesterolconcentrations.Serum
adiponectin concentrations were signiﬁcantly higher in the
PD HDL-high group (P = .02), and BMI, body weight, and
fasting glucoselevelsweresigniﬁcantlylowerinthePDHDL-
high group (Figure 2).
4.Discussion
The adiponectin serum levels in PD patients were similar
to the adiponectin serum levels in young, healthy, normal-
weight subjects matched for BMI. Moreover, a correlation
between adiponectin serum levels and HDL cholesterol
concentrationswas found. The ﬁnding ofa direct correlation
between adiponectin and HDL cholesterol concentrations
is consistent with the known antiatherogenic properties of
adiponectin protein [18]. Low levels of adiponectin are
associated with low levels of HDL cholesterol and this
combination might be an independent cardiovascular risk
factor; on the other hand, high levels of adiponectin are
associated with high levels of HDL cholesterol indicating
protection against cardiovascular events. The growing body
of data suggests that adiponectin reduces cardiovascular risk
in the general population, that is, the risk of developing
type II diabetes, hypertension, and myocardial infarction
[15–17]. To our knowledge, this is the ﬁrst study in which
adiponectinserumlevelshavebeenmeasured inPDpatients.
There is some evidence suggesting that PD patients body
weight is lower than age-matched healthy subjects [2].
We then decided to compare adiponectin levels in PD4 Parkinson’s Disease
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Figure 2: PD patient (n = 30) subgroups based on HDL cholesterol levels: PD HDL-high (HDL cholesterol ≥ 50mg/mL, n = 16) and PD
HDL-low (HDL cholesterol < 50mg/mL,n = 14).Signiﬁcantdiﬀerences in means (±SD) foradiponectin (μg/mL),fastingglucose(mg/dL),
body weight (kg), and BMI (kg/m2)a r es h o w n .∗P-value <.05; ∗∗P-value <.01.
patients with a BMI-matched group, despite a signiﬁcant
diﬀerence in mean age. Interestingly, adiponectin serum
levels were not diﬀerent in the two groups taken into
consideration, indicating that adiponectin might play a role
as a protective factor against cardiovascular disease also
in PD patients. Previous studies were performed in the
general population, focusing on diﬀerences between obese
and nonobese subjects, and between genders. It has been
established that in the general population, the synthesis
of adiponectin is stimulated when the quantity of adipose
tissue diminishes [23], contrary to most other adipokines,
whose synthesis is directly proportional to the increase in
fat mass. To date, the normal range for adiponectin serum
levels has not been established. The mean value of serum
adiponectin concentrations in nonobese subjects is about
10μg/mL; concentrations are lower by more than 50% in
obesesubjects[24,25], takinginto accountdiﬀerenceslinked
to genders. We decided to compare adiponectin levels in
a morbidly obese patient group, age-matched with the PD
group. We observed that adiponectin levels in obese subjects
were signiﬁcantly decreased. Obesity is one of the ﬁrst
cardiovascular risk factors, and the reduction in adiponectin
levels may have a role in this increased risk.
It is known that adiponectin serum concentrations diﬀer
between genders: in nonobese subjects, mean serum levels
i nm e na r el o w e rt h a nt h a ti nw o m e n( 7 . 7± 3.1 versus 10.6
± 7.3μg/mL). This diﬀerence between genders may be due
to androgen eﬀects [26], which occur also in obese subjects
[24]. A larger group is needed to address this issue in PD
patients.
In the present study, we performed a comparison for
adiponectin levels in PD patients with the levels of an age-
matched group of obese patients on one hand and with the
circulating levels of a BMI-matched healthy control group on
the other hand. Since adiponectin is decreased in obesity, in
the comparison with PD patients, adiponectin levels of PD
patients were as expected increased.
However, the levels in PD patients were not diﬀerent
when compared to healthy and young controls. With this
kind of comparison it is hard to know whether the high
adiponectin levels in PD patients are simply a reﬂection
of body weight and body composition, or are intrinsically
diﬀerent in PD subjects. A future study, in a bigger cohort,
both age- and BMI- matched, is needed to clarify this issue.
One issue in research on adiponectin is what form to
measure in the bloodstream. In human serum, it occurs in
the form of various oligomers: trimer, hexamer, and high
molecular weight forms [27, 28]. Both biological activity
and the translation mechanism diﬀer from multimer to
multimer,butithasbeenshown beyonddoubtthattheactive
form is the high molecular weight adiponectin [29, 30].
Much more work is required to establish which isoformsParkinson’s Disease 5
of adiponectin are associated with cardioprotection and to
clarify the transduction mechanisms of receptor-mediated
signals.
The clinical usefulness of adiponectin as a diagnostic/
prognostic marker has yet to be established according to
the outcome of prospective clinical trials. In particular,
information is needed on the predictive value of adiponectin
serum concentrations as compared to other well-known risk
factors. Thus, it is too early to propose the introduction of
adiponectin serum concentrations as a biomarker in clinical
practice.However,thisadipokine appearstobeanimportant
factor to study not only as a potential diagnostic index for
cardiovascular risk, but also as a target for pharmacological
therapy [31].
The correlation we found between adiponectin and
HDL cholesterol suggests that cardiovascular risk is low
in PD patients. In a previous study, we observed a corre-
lation between the duration of disease and HDL choles-
terol concentrations [9]. The lower limit of normal for
HDL cholesterol serum concentrations is usually considered
50mg/dL [32]. For this reason, we decided to subdivide
our patient population into two groups according to this
cut-oﬀ value, which separated patients with normal values
(PD HDL-high) from those with lower abnormal values (PD
HDL-low). PD patients with HDL cholesterol ≥50mg/dL
resulted to have better metabolic protection (and higher
adiponectin levels) as well as normal BMI and fasting
glucose levels. High-density lipoprotein (HDL) cholesterol
is a common and independent protective cardiovascular risk
factor.CardiovascularriskincreasesasHDLcholesterollevels
decrease. While lipid lowering and antidiabetic drugs, such
as statins, ﬁbrates, and PPAR gamma agonists as well as diet
a l o n eh a v eo n l ym a r g i n a le ﬀects on HDL cholesterol serum
levels. On the contrary, physical exercise is able to elevate
HDL levels eﬀectively.
5.Conclusions
In conclusion, this is the ﬁrst study that shows that PD
patientshaveserumadiponectinconcentrationselevatedand
comparable to the levels of young normal-weight subjects
with absence of cardiovascular risk factors. Moreover, the
adiponectin concentrations are related to HDL cholesterol
levels.
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